Literature DB >> 31107158

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Michelle I Echevarria1, Shivanshu Awasthi1, Chia-Ho Cheng1, Anders E Berglund1, Robert J Rounbehler1, Travis A Gerke1, Mandeep Takhar2, Elai Davicioni2, Eric A Klein3, Stephen J Freedland4, Ashley E Ross5, Edward M Schaeffer6, Robert B Den7, John L Cleveland1, Jong Y Park1, Walter Rayford8, Kosj Yamoah1.   

Abstract

PURPOSE: Most prostate cancer in African American men lacks the ETS (E26 transforming specific) family fusion event (ETS-). We aimed to establish clinically relevant biomarkers in African American men by studying ETS dependent gene expression patterns to identified race specific genes predictive of outcomes.
MATERIALS AND METHODS: Two multicenter cohorts of a total of 1,427 men were used for the discovery and validation (635 and 792 men, respectively) of race specific predictive biomarkers. We used false discovery rate adjusted q values to identify race and ETS dependent genes which were differentially expressed in African American men who experienced biochemical recurrence within 5 years. Principal component modeling along with survival analysis was done to assess the accuracy of the gene panel in predicting recurrence.
RESULTS: We identified 3,047 genes which were differentially expressed based on ETS status. Of these genes 362 were differentially expressed in a race specific manner (false discovery rate 0.025 or less). A total of 81 genes were race specific and over expressed in African American men who experienced biochemical recurrence. The final gene panel included APOD, BCL6, EMP1, MYADM, SRGN and TIMP3. These genes were associated with 5-year biochemical recurrence (HR 1.97, 95% CI 1.27-3.06, p = 0.002) and they improved the predictive accuracy of clinicopathological variables only in African American men (60-month time dependent AUC 0.72).
CONCLUSIONS: In an effort to elucidate biological features associated with prostate cancer aggressiveness in African American men we identified ETS dependent biomarkers predicting early onset biochemical recurrence only in African American men. Thus, these ETS dependent biomarkers representing ideal candidates for biomarkers of aggressive disease in this patient population.

Entities:  

Keywords:  African Americans; biomarkers; gene expression regulation; local; neoplasm recurrence; neoplastic; prostatic neoplasms; tumor

Mesh:

Substances:

Year:  2019        PMID: 31107158      PMCID: PMC7882398          DOI: 10.1097/JU.0000000000000193

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis.

Authors:  Xin-Jian Li; Choon Kiat Ong; Yun Cao; Yan-Qun Xiang; Jian-Yong Shao; Aikseng Ooi; Li-Xia Peng; Wen-Hua Lu; Zhongfa Zhang; David Petillo; Li Qin; Ying-Na Bao; Fang-Jing Zheng; Claramae Shulyn Chia; N Gopalakrishna Iyer; Tie-Bang Kang; Yi-Xin Zeng; Khee Chee Soo; Jeffrey M Trent; Bin Tean Teh; Chao-Nan Qian
Journal:  Cancer Res       Date:  2011-02-02       Impact factor: 12.701

2.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

3.  Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.

Authors:  Alba Torres; Mohammed Alshalalfa; Scott A Tomlins; Nicholas Erho; Ewan A Gibb; Jijumon Chelliserry; Lony Lim; Lucia L C Lam; Sheila F Faraj; Stephania M Bezerra; Elai Davicioni; Kasra Yousefi; Ashley E Ross; George J Netto; Edward M Schaeffer; Tamara L Lotan
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

4.  TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Authors:  Samson W Fine; Anuradha Gopalan; Margaret A Leversha; Hikmat A Al-Ahmadie; Satish K Tickoo; Qin Zhou; Jaya M Satagopan; Peter T Scardino; William L Gerald; Victor E Reuter
Journal:  Mod Pathol       Date:  2010-06-18       Impact factor: 7.842

5.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.

Authors:  Sven Perner; Matthias D Hofer; Robert Kim; Rajal B Shah; Haojie Li; Peter Möller; Richard E Hautmann; Juergen E Gschwend; Rainer Kuefer; Mark A Rubin
Journal:  Hum Pathol       Date:  2007-02-22       Impact factor: 3.466

6.  Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

Authors:  Kosj Yamoah; Michael H Johnson; Voleak Choeurng; Farzana A Faisal; Kasra Yousefi; Zaid Haddad; Ashley E Ross; Mohammed Alshalafa; Robert Den; Priti Lal; Michael Feldman; Adam P Dicker; Eric A Klein; Elai Davicioni; Timothy R Rebbeck; Edward M Schaeffer
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

7.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

8.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

9.  Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines.

Authors:  Angeliki Korpetinou; Dionysios J Papachristou; Angeliki Lampropoulou; Panagiotis Bouris; Vassiliki T Labropoulou; Argyrios Noulas; Nikos K Karamanos; Achilleas D Theocharis
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

10.  Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Authors:  Anders E Berglund; Robert J Rounbehler; Travis Gerke; Shivanshu Awasthi; Chia-Ho Cheng; Mandeep Takhar; Elai Davicioni; Mohammed Alshalalfa; Nicholas Erho; Eric A Klein; Stephen J Freedland; Ashley E Ross; Edward M Schaeffer; Bruce J Trock; Robert B Den; John L Cleveland; Jong Y Park; Jasreman Dhillon; Kosj Yamoah
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-10-26       Impact factor: 5.554

View more
  7 in total

1.  Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.

Authors:  Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari
Journal:  Commun Biol       Date:  2021-06-03

2.  Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race.

Authors:  Kevin H Kensler; Shivanshu Awasthi; Mohamed Alshalalfa; Bruce J Trock; Stephen J Freedland; Michael R Freeman; Sungyong You; Brandon A Mahal; Robert B Den; Adam P Dicker; R Jeffrey Karnes; Eric A Klein; Priti Lal; Yang Liu; Elai Davicioni; Walter Rayford; Kosj Yamoah; Timothy R Rebbeck
Journal:  Eur Urol Open Sci       Date:  2022-04-26

3.  Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.

Authors:  Stephen J Freedland; Kosj Yamoah; Shivanshu Awasthi; Anders Berglund; Julieta Abraham-Miranda; Robert J Rounbehler; Kevin Kensler; Amparo Serna; Adriana Vidal; Sungyong You; Michael R Freeman; Elai Davicioni; Yang Liu; R Jeffrey Karnes; Eric A Klein; Robert B Den; Bruce J Trock; Joshua D Campbell; David J Einstein; Raavi Gupta; Steven Balk; Priti Lal; Jong Y Park; John L Cleveland; Timothy R Rebbeck
Journal:  Clin Cancer Res       Date:  2020-10-09       Impact factor: 13.801

4.  A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.

Authors:  Min Zhou; Yan Chen; Xuyu Gu; Cailian Wang
Journal:  Pathol Oncol Res       Date:  2022-08-19       Impact factor: 2.874

5.  Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease.

Authors:  Hong Yuen Wong; Quanhu Sheng; Amanda B Hesterberg; Sarah Croessmann; Brenda L Rios; Khem Giri; Jorgen Jackson; Adam X Miranda; Evan Watkins; Kerry R Schaffer; Meredith Donahue; Elizabeth Winkler; David F Penson; Joseph A Smith; S Duke Herrell; Amy N Luckenbaugh; Daniel A Barocas; Young J Kim; Diana Graves; Giovanna A Giannico; Jeffrey C Rathmell; Ben H Park; Jennifer B Gordetsky; Paula J Hurley
Journal:  Nat Commun       Date:  2022-10-13       Impact factor: 17.694

6.  TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.

Authors:  Kosj Yamoah; Priti Lal; Shivanshu Awasthi; Arash O Naghavi; Robert J Rounbehler; Travis Gerke; Anders E Berglund; Julio M Pow-Sang; Edward M Schaeffer; Jasreman Dhillon; Jong Y Park; Timothy R Rebbeck
Journal:  Prostate       Date:  2020-11-03       Impact factor: 4.104

Review 7.  Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.

Authors:  Zachary S Dovey; Sujit S Nair; Dimple Chakravarty; Ashutosh K Tewari
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.